Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial

被引：0
|
作者：
T. Shiroiwa
T. Fukuda
K. Shimozuma
M. Mouri
Y. Hagiwara
H. Doihara
H. Akabane
M. Kashiwaba
T. Watanabe
Y. Ohashi
H. Mukai
机构：
[1] National Institute of Public Health,Department of Health and Welfare Services
[2] Ritsumeikan University,Department of Biomedical Sciences, College of Life Sciences
[3] Kanagawa Academy of Science and Technology (KAST),Department of Biostatistics, School of Public Health
[4] The University of Tokyo,Breast and Endocrine Surgery Department
[5] Okayama University Hospital,Department of Surgery
[6] Hokkaido P.W.F.A.C. Asahikawa-Kosei General Hospital,Department of Surgery
[7] Iwate Medical University,Department of Breast Surgery
[8] Sendai Medical Center,Department of Integrated Science and Engineering
[9] Chuo University,Division of Breast and Medical Oncology
[10] National Cancer Center Hospital East,undefined
来源：
Quality of Life Research | 2017年 / 26卷
关键词：
Breast cancer; EQ-5D; Health-related quality of life; Randomized controlled trial; S-1; Taxane;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：445 / 453
页数：8
相关论文
共 47 条
  • [1] Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial
    Shiroiwa, T.
    Fukuda, T.
    Shimozuma, K.
    Mouri, M.
    Hagiwara, Y.
    Doihara, H.
    Akabane, H.
    Kashiwaba, M.
    Watanabe, T.
    Ohashi, Y.
    Mukai, H.
    QUALITY OF LIFE RESEARCH, 2017, 26 (02) : 445 - 453
  • [2] LONG-TERM EQ-5D SCORE FOR PATIENTS WITH METASTATIC BREAST CANCER; COMPARISON OF FIRST-LINE ORAL S-1 AND TAXANE THERAPIES IN THE RANDOMIZED "SELECT" TRIAL
    Fukuda, T.
    Shiroiwa, T.
    Shimozuma, K.
    Mouri, M.
    Doihara, H.
    Akabane, H.
    Kashiwaba, M.
    Watanabe, T.
    Hagiwara, Y.
    Ohashi, Y.
    Mukai, H.
    VALUE IN HEALTH, 2015, 18 (07) : A467 - A467
  • [3] Biomarker analysis of S-1 in SELECT-BC: A randomized phase III study of taxane versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT-BC EURECA).
    Hara, Fumikata
    Mukai, Hirofumi
    Ohsumi, Shozo
    Yotsumoto, Daisuke
    Takashima, Tsutomu
    Hozumi, Yasuo
    Watanabe, Takanori
    Saito, Tsuyoshi
    Watanabe, Ken-ichi
    Tsurutani, Junji
    Toyama, Tatsuya
    Akabane, Hiromitsu
    Nishimura, Reiki
    Taira, Naruto
    Uemura, Yukari
    Ohashi, Yasuo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Randomized phase III study of taxane versus TS-1 as first-line treatment for metastatic breast cancer (SELECT BC).
    Hara, Fumikata
    Matsubara, Nobuaki
    Saito, Tsuyoshi
    Takano, Toshimi
    Park, Youngjin
    Toyama, Tatsuya
    Hozumi, Yasuo
    Tsurutani, Junji
    Moth, Shigeru
    Takashima, Tsutomu
    Watanabe, Takanori
    Sagara, Yoshiaki
    Nishimura, Reiki
    Ohashi, Yasuo
    Mukai, Hirofumi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Randomized phase III trial of taxanes versus S-1 as first-line chemotherapy for metastatic breast cancer (SELECT BC: CSPOR-MBC01)
    Watanabe, Takanori
    Shimozuma, Kojiro
    Imi, Kentaro
    Doihara, Hiroyoshi
    Akabane, Hiromitsu
    Ueo, Hiroaki
    Ohno, Shinji
    Kashiwaba, Masahiro
    Fukuuchi, Atsushi
    Watanabe, Kenichi
    Tsuneizumi, Michiko
    Isaka, Hirotsugu
    Uemura, Yukari
    Ohashi, Yasuo
    Mukai, Hirofumi
    CANCER RESEARCH, 2015, 75
  • [6] COST-EFFECTIVENESS OF FIRST-LINE S-1 THERAPY FOR METASTATIC BREAST CANCER PATIENTS COMPARED WITH TAXANES: AN ANALYSIS BASED ON THE RANDOMIZED PHASE III SELECT BC TRIAL
    Shiroiwa, T.
    Fukuda, T.
    Shimozuma, K.
    Mouri, M.
    Hagiwara, Y.
    Kawahara, T.
    Ohsumi, S.
    Hozumi, Y.
    Sagara, Y.
    Ohashi, Y.
    Mukai, H.
    VALUE IN HEALTH, 2016, 19 (07) : A737 - A737
  • [7] Evaluation of oral S-1 as a first-line chemotherapy for metastatic HER2-negative breast cancer: An analysis of two randomized phase III studies (SELECT BC-CONFIRM and SELECT BC)
    Nishimura, Reiki
    Mukai, Hirofumi
    Uemura, Yukari
    Akabane, Hiromitsu
    Park, Youngjin
    Takahashi, Masato
    Sagara, Yoshiaki
    Takashima, Tsutomu
    Fujisawa, Tomomi
    Hozumi, Yasuo
    Kawahara, Takuya
    Watanabe, Takanori
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Responder analyses of patient-reported outcomes for evaluating the clinical significance of first-line S-1 over taxane therapy among patients with metastatic breast cancer: the open-label randomized phase III SELECT-BC trial
    Kawahara, Takuya
    Shimozuma, Kojiro
    Shiroiwa, Takeru
    Hagiwara, Yasuhiro
    Uemura, Yukari
    Watanabe, Takanori
    Fukuda, Takashi
    Ohashi, Yasuo
    Mukai, Hirofumi
    QUALITY OF LIFE RESEARCH, 2016, 25 : 116 - 116
  • [9] Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial
    Takeru Shiroiwa
    Takashi Fukuda
    Kojiro Shimozuma
    Mitsuko Mouri
    Yasuhiro Hagiwara
    Takuya Kawahara
    Shozo Ohsumi
    Yasuo Hozumi
    Yoshiaki Sagara
    Yasuo Ohashi
    Hirofumi Mukai
    BMC Cancer, 17
  • [10] Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial
    Shiroiwa, Takeru
    Fukuda, Takashi
    Shimozuma, Kojiro
    Mouri, Mitsuko
    Hagiwara, Yasuhiro
    Kawahara, Takuya
    Ohsumi, Shozo
    Hozumi, Yasuo
    Sagara, Yoshiaki
    Ohashi, Yasuo
    Mukai, Hirofumi
    BMC CANCER, 2017, 17
12345